Moderna Inc (MRNA)vsNovaBay Pharmaceuticals Inc (NBY)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NBY
NovaBay Pharmaceuticals Inc
$0.09
+22.64%
HEALTHCARE · Cap: $51.92M
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 21527% more annual revenue ($2.23B vs $10.30M). NBY leads profitability with a 0.0% profit margin vs -141.4%. NBY earns a higher WallStSmart Score of 40/100 (D).
MRNA
Avoid21
out of 100
Grade: F
NBY
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NBY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 350.1%
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NBY
The strongest argument for NBY centers on Operating Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NBY
The primary concerns for NBY are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NBY is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NBY generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
NBY scores higher overall (40/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
NovaBay Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company is headquartered in Emeryville, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?